Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue
Background: The PD-L1 level is mainly used to predict the effect of drug treatment in patients with melanoma. Despite the radical nature of surgery in these patients, the rate of disease progression remains high. Therefore, it is important to study the relation between the PD-L1 level in the tumor...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Scientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1
2023-11-01
|
| Series: | Инновационная медицина Кубани |
| Subjects: | |
| Online Access: | https://www.innovmedkub.ru/jour/article/view/764 |
| _version_ | 1797276900332142592 |
|---|---|
| author | S. S. Yargunin I. V. Reshetov Ya. N. Shoykhet S. I. Samoylova O. Yu. Chukhrai S. N. Pyatakov |
| author_facet | S. S. Yargunin I. V. Reshetov Ya. N. Shoykhet S. I. Samoylova O. Yu. Chukhrai S. N. Pyatakov |
| author_sort | S. S. Yargunin |
| collection | DOAJ |
| description | Background: The PD-L1 level is mainly used to predict the effect of drug treatment in patients with melanoma. Despite the radical nature of surgery in these patients, the rate of disease progression remains high. Therefore, it is important to study the relation between the PD-L1 level in the tumor and surgical treatment options for cutaneous melanoma and patient survival.Objective: To analyze the effect of the PD-L1 level in patients with primary cutaneous melanoma at different levels of tumor excision and options for closing the surgical defect.Materials and methods: We used data of 143 patients with stage 0IIIC primary cutaneous melanoma who were randomized into 2 groups: the main group (wide excision of the tumor and plastic repair of the tissue defect) and the comparison group (standard tumor removal) with different PD-L1 levels (IC [immune cells] %). The 5-year survival of patients was estimated.Results: We found the mutual dependence of the PD-L1 level and the survival of patients with stage 0-IIC melanoma on the extent of the tissues removed and the option for closing the defect.Conclusions: The 5year progressionfree survival in patients with stage 0IIA primary cutaneous melanoma was higher than that of those with stage IIB-IIC melanoma regardless of the PD-L1 level. In patients with stage 0-IIA primary cutaneous melanoma and the low PD-L1 level (˂5), progressionfree survival was 26.3% higher (P = .013) than that of those with the high PD-L1 level (≥5). In patients from the main group with stage 0-IIA melanoma and the low PDL1 level (˂5), progressionfree survival was 25% higher (P = .017) and overall survival was 16.7% higher (P = .045) compared with patients from the control group with the same PD-L1 level. In patients from the main group with stage 0-IIC melanoma and the high PD-L1 level (≥5), the 5-year progressionfree survival was 21.2% higher (P = .033) compared with patients from the comparison group. |
| first_indexed | 2024-03-07T15:35:06Z |
| format | Article |
| id | doaj.art-b2ede96c26bd4e40857231880592a8d1 |
| institution | Directory Open Access Journal |
| issn | 2541-9897 |
| language | Russian |
| last_indexed | 2024-03-07T15:35:06Z |
| publishDate | 2023-11-01 |
| publisher | Scientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1 |
| record_format | Article |
| series | Инновационная медицина Кубани |
| spelling | doaj.art-b2ede96c26bd4e40857231880592a8d12024-03-05T11:12:32ZrusScientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1Инновационная медицина Кубани2541-98972023-11-010410.35401/2541-9897-2023-8-4-42-50411Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor TissueS. S. Yargunin0I. V. Reshetov1Ya. N. Shoykhet2S. I. Samoylova3O. Yu. Chukhrai4S. N. Pyatakov5Clinical Oncology Dispensary No. 1L.L. Levshin Institute of Cluster Oncology, I.M. Sechenov First Moscow State Medical University; N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical-Biological AgencyAltai State Medical UniversityN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical-Biological AgencyClinical Oncology Dispensary No. 1Kuban State Medical UniversityBackground: The PD-L1 level is mainly used to predict the effect of drug treatment in patients with melanoma. Despite the radical nature of surgery in these patients, the rate of disease progression remains high. Therefore, it is important to study the relation between the PD-L1 level in the tumor and surgical treatment options for cutaneous melanoma and patient survival.Objective: To analyze the effect of the PD-L1 level in patients with primary cutaneous melanoma at different levels of tumor excision and options for closing the surgical defect.Materials and methods: We used data of 143 patients with stage 0IIIC primary cutaneous melanoma who were randomized into 2 groups: the main group (wide excision of the tumor and plastic repair of the tissue defect) and the comparison group (standard tumor removal) with different PD-L1 levels (IC [immune cells] %). The 5-year survival of patients was estimated.Results: We found the mutual dependence of the PD-L1 level and the survival of patients with stage 0-IIC melanoma on the extent of the tissues removed and the option for closing the defect.Conclusions: The 5year progressionfree survival in patients with stage 0IIA primary cutaneous melanoma was higher than that of those with stage IIB-IIC melanoma regardless of the PD-L1 level. In patients with stage 0-IIA primary cutaneous melanoma and the low PD-L1 level (˂5), progressionfree survival was 26.3% higher (P = .013) than that of those with the high PD-L1 level (≥5). In patients from the main group with stage 0-IIA melanoma and the low PDL1 level (˂5), progressionfree survival was 25% higher (P = .017) and overall survival was 16.7% higher (P = .045) compared with patients from the control group with the same PD-L1 level. In patients from the main group with stage 0-IIC melanoma and the high PD-L1 level (≥5), the 5-year progressionfree survival was 21.2% higher (P = .033) compared with patients from the comparison group.https://www.innovmedkub.ru/jour/article/view/764cutaneous melanomawide excisionpdl1 levelprogressionfree survivaloverall survival |
| spellingShingle | S. S. Yargunin I. V. Reshetov Ya. N. Shoykhet S. I. Samoylova O. Yu. Chukhrai S. N. Pyatakov Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue Инновационная медицина Кубани cutaneous melanoma wide excision pdl1 level progressionfree survival overall survival |
| title | Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue |
| title_full | Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue |
| title_fullStr | Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue |
| title_full_unstemmed | Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue |
| title_short | Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue |
| title_sort | survival of patients with primary cutaneous melanoma and the surgical treatment option based on the level of the surface protein pd l1 in the tumor tissue |
| topic | cutaneous melanoma wide excision pdl1 level progressionfree survival overall survival |
| url | https://www.innovmedkub.ru/jour/article/view/764 |
| work_keys_str_mv | AT ssyargunin survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue AT ivreshetov survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue AT yanshoykhet survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue AT sisamoylova survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue AT oyuchukhrai survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue AT snpyatakov survivalofpatientswithprimarycutaneousmelanomaandthesurgicaltreatmentoptionbasedonthelevelofthesurfaceproteinpdl1inthetumortissue |